| Citation:L M. Shahsuvaryan.Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion.Int J Ophthalmol 2012;5(6):759-770,doi:10.3980/j.issn.2222-3959.2012.06.20 |
|
| Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion |
| Received:July 11, 2012 Revised:November 19, 2012 |
| Email this Article Add to Favorites Print |
| DOI：10.3980/j.issn.2222-3959.2012.06.20 |
| Key Words:retina retinal vein occlusion medical treatment intravitreal injections |
| Fund Project: |
|
|
| Hits: 1493 |
| Download times: 686 |
| Abstract: |
| Retinal vein occlusion (RVO) is the most common visually disabling disease affecting the retina after diabetic retinopathy. Although the disease entity has long been known, its management is still controversial. Macular edema is the main reason for decreased visual acuity (VA) in this retinal vascular disorder. Recently the vitreous cavity has increasingly been used as a reservoir of drugs for the direct treatment of macular edema through intravitreal injection route. The most widely injected drugs so far have been triamcinolone acetonide (TA) and bevacizumab. The objective of this review is to evaluate the evidence and discuss the rationale behind the recent suggestions that intravitreal pharmacotherapy by corticosteroids and anti-vascular endothelial growth factors may be useful in the treatment of retinal vein occlusion. |
| Supplementary Material |
| PDF Fulltext Download reader View/Add Comment |
|
